SEC Form 4 · accession 0001179110-16-032838
SUNESIS PHARMACEUTICALS INC · SNSS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Geoffrey M. Parker
Director
Period of report
Dec 8, 2016
Accepted (ET)
Dec 12, 2016 · 6:43 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001061027
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 8, 2016 | P | 3,146 | $3.865 | A | 65,151 | D | |
| Common StockF2 | Dec 9, 2016 | P | 594 | $3.9018 | A | 65,745 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $3.80 to $3.93, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) of this Form 4.
- F2The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $3.79 to $3.95, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (2) of this Form 4.